drugset
drugset / Trial / NCT00653419

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

NCT00653419 ↗

Phase 1 Completed 48 enrolled Par Pharmaceutical, Inc. Phoenix International Life Sciences, Inc. · collab
RandomizedCrossoverOpen-label

Summary

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Timeline

Start
1998-06
Primary completion
1998-09
Completion
1998-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Buspirone Small molecule 30 mg —

Indications

No indication recorded.